Current Status of Therapeutic Approaches and Vaccines for SARS-CoV-2

References

• Wu Z , McGooganJM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA232(13), 1239–1242 (2020).
   Google Scholar
• Peeri NC , ShresthaN, RahmanMSet al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int. J. Epidemiol. 49(3), 717–726 (2020).
   PubMed Web of Science ®Google Scholar
• Kannan S , AliPSS, SheezaA, HemalathaK. COVID-19 (novel coronavirus 2019) – recent trends. Eur. Rev. Med. Pharmacol. Sci.24(4), 2006–2011 (2020).
   PubMed Web of Science ®Google Scholar
• Giacomelli A , PezzatiL, ContiFet al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin. Infect. Dis.70(15), 889–890 (2020).
   Google Scholar
• Zhang H , KangZ, GongHet al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. BioRxiv doi:https://doi.org/10.1101/2020.01.30.927806 (2020) ( Epub ahead of print).
   Google Scholar
• Duan K , LiuB, LiCet al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA117(17), 9490–9496 (2020).
   PubMed Web of Science ®Google Scholar
• World Health Organization . DRAFT landscape of COVID-19 candidate vaccines. www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1 WHOWDloC-cvA
   Google Scholar
• Ahmed SF , QuadeerAA, McKayMR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses12(3), 254 (2020).
   PubMed Web of Science ®Google Scholar
• Enayatkhani M , HasaniazadM, FaeziSet al. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study. J. Biomol. Struct. Dyn.39(8), 2857–2872 (2021).
   PubMed Web of Science ®Google Scholar
• World Health Organization . Accelerating a safe and effective COVID-19 vaccine (2020). www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine
   Google Scholar
• Andersen PI , IanevskiA, LysvandHet al. Discovery and development of safe-in-man broad-spectrum antiviral agents. IJID.93, 268–276 (2020).
   PubMed Web of Science ®Google Scholar
• Gordon DE , JangGM, BouhaddouMet al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. BioRxiv doi:https://doi.org/10.1101/2020.03.22.002386 (2020) ( Epub ahead of print).
   Google Scholar
• Chan JF-W , KokK-H, ZhuZet al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect.9(1), 221–236 (2020).
   PubMed Web of Science ®Google Scholar
• Wan Y , ShangJ, GrahamRet al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol.94(7), e00127–20 (2020).
   PubMed Web of Science ®Google Scholar
• Bui LMG . Staphylococcus aureus: stress response and its roles in pathogenesis. Doctoral Dissertation submitted to The University of Adelaide, Australia. (2015).
   Google Scholar
• Ceraolo C , GiorgiFM. Genomic variance of the 2019-nCoV coronavirus. J. Med. Virol.92(5), 522–528 (2020).
   PubMed Web of Science ®Google Scholar
• Paraskevis D , KostakiEG, MagiorkinisGet al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect. Genet. Evol.79, 104212 (2020).
   PubMed Web of Science ®Google Scholar
• Calligari P , BoboneS, RicciG, BocediA. Molecular investigation of SARS-CoV-2 proteins and their interactions with antiviral drugs. Viruses12(4), 445 (2020).
   PubMed Web of Science ®Google Scholar
• Mirza MU , FroeyenM. Structural elucidation of SARS-CoV-2 vital proteins: computational methods reveal potential drug candidates against main protease, Nsp12 RNA-dependent RNA polymerase and Nsp13 helicase. J. Pharm. Anal.10(4), 320–328 (2020).
   PubMed Web of Science ®Google Scholar
• Dai W , ZhangB, SuHet al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science368(6497), 1331–1335 (2020).
   PubMed Web of Science ®Google Scholar
• Agostini ML , AndresEL, SimsACet al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio.9(2), e00221–00218 (2018).
   PubMed Web of Science ®Google Scholar
• Warren TK , JordanR, LoMKet al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature531(7594), 381–385 (2016).
   PubMed Web of Science ®Google Scholar
• Tchesnokov EP , FengJY, PorterDP, GötteM. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses11(4), 326 (2019).
   PubMed Web of Science ®Google Scholar
• Lo MK , JordanR, ArveyAet al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep.7, 43395 (2017).
   PubMed Web of Science ®Google Scholar
• Sheahan TP , SimsAC, GrahamRLet al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med.9(396), (2017).
   PubMed Web of Science ®Google Scholar
• Brown AJ , WonJJ, GrahamRLet al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir. Res.169, 104541 (2019).
   PubMed Web of Science ®Google Scholar
• Williamson B , FeldmannF, SchwarzBet al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. BioRxiv doi:https://doi.org/10.1101/2020.04.15.043166 (2020) ( Epub ahead of print).
   Google Scholar
• Holshue ML , DeBoltC, LindquistSet al. First case of 2019 novel coronavirus in the United States. NEJM.382(10), 929–936 (2020).
   PubMed Web of Science ®Google Scholar
• Jacobs M , RodgerA, BellDJet al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet388(10043), 498–503 (2016).
   PubMed Web of Science ®Google Scholar
• Mulangu S , DoddLE, DaveyRTJret al. A randomized, controlled trial of Ebola virus disease therapeutics. New Engl. J. Med.381(24), 2293–2303 (2019).
   PubMed Web of Science ®Google Scholar
• Wang Y , ZhangD, DuGet al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet395(10236), 1569–1578 (2020).
   PubMed Web of Science ®Google Scholar
• Ko W-C , RolainJ-M, LeeN-Yet al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int. J. Antimicrob. Agents55(4), 105933 (2020).
   PubMed Web of Science ®Google Scholar
• Jie Z , HeH, XiH, ZhiZ. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi.43(3), 185–188 (2020).
   PubMedGoogle Scholar
• Vincent MJ , BergeronE, BenjannetSet al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J.2(1), 69 (2005).
   PubMed Web of Science ®Google Scholar
• Horby P , LimWS, EmbersonJRet al. Dexamethasone in hospitalized patients with Covid-19 – preliminary report. New Engl. J. Med.384(8), 693–704 (2020).
   PubMed Web of Science ®Google Scholar
• Wang M , CaoR, ZhangLet al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res.30(3), 269–271 (2020).
   PubMed Web of Science ®Google Scholar
• Gautret P , LagierJ-C, ParolaPet al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents56(1), 105949 (2020).
   PubMed Web of Science ®Google Scholar
• Gao J , TianZ, YangX. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends14(1), 72–73 (2020).
   PubMed Web of Science ®Google Scholar
• Yao X , YeF, ZhangMet al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.71(5), 732–739 (2020).
   PubMedGoogle Scholar
• Cao Y-C , DengQ-X, DaiS-X. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence. Travel Med. Infect. Dis.35(1), 101647 (2020).
   PubMedGoogle Scholar
• Intson K , KumarS, BottaAet al. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19. Swiss Med. Weekly150(1718), w20262 (2020).
   PubMedGoogle Scholar
• World Health Organization . Solidarity clinical trial for COVID-19 treatments (2020). www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
   Google Scholar
• Costanzo M , DeGiglio M, RovielloG. SARS CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr. Med. Chem.27(27), 4535–4541 (2020).
   Web of Science ®Google Scholar
• Cheng Y , WongR, SooYet al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis.24(1), 44–46 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou B , ZhongN, GuanY. Treatment with convalescent plasma for influenza A (H5N1) infection. New Engl. J. Med.357(14), 1450–1451 (2007).
   PubMed Web of Science ®Google Scholar
• Hung IF , ToKK, LeeC-Ket al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis.52(4), 447–456 (2011).
   PubMed Web of Science ®Google Scholar
• Ko J-H , SeokH, ChoSYet al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir. Ther.23(7), 617–622 (2018).
   PubMed Web of Science ®Google Scholar
• Mair-Jenkins J , Saavedra-CamposM, BaillieJKet al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis.211(1), 80–90 (2015).
   PubMed Web of Science ®Google Scholar
• Shen C , WangZ, ZhaoFet al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA.323(16), 1582–1589 (2020).
   PubMed Web of Science ®Google Scholar
• Luo P , LiuY, QiuLet al. Tocilizumab treatment in COVID-19: a single center experience. J. Med. Virol.92(7), 814–818 (2020).
   PubMed Web of Science ®Google Scholar